Neoadjuvant immune checkpoint therapy trialled for NSCLC
Two different phase 2 trials suggest most patients can go on to have full resection
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Two phase 2 trials of preoperative immune checkpoint therapy have shown that it does not compromise surgery in patients with early non-small cell lung cancer (NSCLC).
Results of the two French trials — IONESCO and PRINCEPS — were reported at the European Society for Medical Oncology (ESMO) virtual congress 2020.
In IONESCO, 46 patients with early stage NSCLC were treated with